Current Insights and Future Perspectives into Mechanisms of Drug Resistance in Gastrointestinal Cancers

Dear Colleagues,

Gastrointestinal cancers, including colorectal, gastric, esophageal, and pancreatic cancers, are significant contributors to global cancer morbidity and mortality rates. While considerable progress has been made in developing targeted therapies and immunotherapies for GI cancers, the emergence of drug resistance remains a major obstacle in achieving successful long-term treatment outcomes.

This Special Issue on "Current Insights and Future Perspectives Into Mechanisms of Drug Resistance in Gastrointestinal Cancers" aims to provide a comprehensive overview of the current understanding and emerging research in the field of drug resistance in gastrointestinal (GI) cancers. This Special Issue brings together leading researchers and experts to shed light on the complex mechanisms underlying drug resistance and explore potential strategies to overcome this challenge.

This Special Issue will delve into various aspects of drug resistance mechanisms in GI cancers, such as genetic alterations, epigenetic modifications, tumor microenvironment factors, and host immunity. The contributors will present cutting-edge research findings, including novel molecular pathways and signaling networks that drive drug resistance in GI cancers. They will also explore the role of tumor heterogeneity, cancer stem cells, and the interplay between cancer cells and stromal components in promoting resistance. Moreover, this Special Issue will discuss the clinical implications of drug resistance and its impact on treatment response and patient outcomes. The contributors will critically evaluate the existing therapeutic approaches, including the development of combination therapies, personalized medicine strategies, and the repurposing of drugs to overcome resistance.

By presenting the current insights and future perspectives on mechanisms of drug resistance in GI cancers, this Special Issue aims to foster a deeper understanding of this complex problem and inspire innovative research directions. Ultimately, it aims to contribute to the development of more effective treatment strategies that can improve the prognosis and survival rates for patients with GI cancers.

Dr. Mohammed Sikander
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gastric cancer
• pancreatic cancer
• esophageal cancer
• colorectal cancer
• tumor microenvironment
• immunotherapy
• oncogene
• epigenetics
• chemoresistance
• biomarkers